首页 > 最新文献

Gastroenterology Research最新文献

英文 中文
Expanding the Use of Endoscopic Retrograde Cholangiopancreatography in Pediatrics: A National Database Analysis of Demographics and Complication Rates. 扩大内窥镜逆行胆管造影在儿科的应用:人口统计学和并发症发生率的国家数据库分析。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 DOI: 10.14740/gr1503
Eric Lorio, Chris Moreau, Joel Edmund Michalek, Sandeep Patel

Background: This study aimed to aid in risk assessment of pediatric endoscopic retrograde cholangiopancreatography (ERCP) candidates by utilizing a national pediatric database with a large sample to assess how patient characteristics may affect ERCP complication rates.

Methods: The Kids' Inpatient Database (KID) is a sample of pediatric discharges in states participating in the Healthcare Cost and Utilization Project (HCUP). This database provides demographic information, hospitalization duration, and outcome information for hospitalizations during which an ERCP occurred. International Classification of Diseases (ICD) codes were used to determine the hospitalization indication. ERCP complication rate was ascertained via ICD codes. All statistical analyses were performed using SAS 9.4.

Results: Complications were seen in 5.4% of hospitalizations with mortality observed in less than 0.2%. This analysis captured a large Hispanic population, specifically in the South and West regions. Gallbladder calculus and cholecystitis were more likely to occur in females. A higher percentage of patients in the age 10 - 17 group were female (72.2% vs. 52.7%, P < 0.01) and Hispanic (33.4% vs. 22.7%, P < 0.01) compared to the age 0 - 9 group. Age 0 - 5 and male gender were associated with lower routine home discharge rates and longer lengths of stay. Complications occurred at a higher rate in ages 0 - 5, though the difference was not statistically significant.

Conclusions: ERCP is a safe procedure for pediatric patients with low complication rates and rare mortality. We found statistically significant differences in the procedure indications between pediatric age groups, races, and genders. Age ≤ 5 years and male gender were associated with more complicated healthcare courses.

背景:本研究旨在通过利用国家大样本儿科数据库来评估患者特征如何影响ERCP并发症发生率,从而帮助评估儿童内窥镜逆行胆管胰胆管造影(ERCP)候选人的风险。方法:儿童住院病人数据库(KID)是参与医疗保健成本和利用项目(HCUP)的各州儿童出院的样本。该数据库提供了发生ERCP期间的人口统计信息、住院时间和住院结果信息。采用国际疾病分类(ICD)代码确定住院指征。通过ICD编码确定ERCP并发症发生率。所有统计分析均采用SAS 9.4进行。结果:并发症发生率为5.4%,死亡率低于0.2%。这项分析涵盖了大量的西班牙裔人口,特别是在南部和西部地区。胆结石和胆囊炎在女性中更容易发生。与0 ~ 9岁组相比,10 ~ 17岁组患者中女性(72.2%比52.7%,P < 0.01)和西班牙裔(33.4%比22.7%,P < 0.01)比例较高。年龄0 - 5岁和男性与较低的常规出院率和较长的住院时间有关。0 ~ 5岁并发症发生率较高,但差异无统计学意义。结论:ERCP是一种安全的手术,并发症发生率低,死亡率低。我们发现,在儿童年龄组、种族和性别之间,手术指征有统计学上的显著差异。年龄≤5岁和男性与更复杂的保健过程相关。
{"title":"Expanding the Use of Endoscopic Retrograde Cholangiopancreatography in Pediatrics: A National Database Analysis of Demographics and Complication Rates.","authors":"Eric Lorio,&nbsp;Chris Moreau,&nbsp;Joel Edmund Michalek,&nbsp;Sandeep Patel","doi":"10.14740/gr1503","DOIUrl":"https://doi.org/10.14740/gr1503","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to aid in risk assessment of pediatric endoscopic retrograde cholangiopancreatography (ERCP) candidates by utilizing a national pediatric database with a large sample to assess how patient characteristics may affect ERCP complication rates.</p><p><strong>Methods: </strong>The Kids' Inpatient Database (KID) is a sample of pediatric discharges in states participating in the Healthcare Cost and Utilization Project (HCUP). This database provides demographic information, hospitalization duration, and outcome information for hospitalizations during which an ERCP occurred. International Classification of Diseases (ICD) codes were used to determine the hospitalization indication. ERCP complication rate was ascertained via ICD codes. All statistical analyses were performed using SAS 9.4.</p><p><strong>Results: </strong>Complications were seen in 5.4% of hospitalizations with mortality observed in less than 0.2%. This analysis captured a large Hispanic population, specifically in the South and West regions. Gallbladder calculus and cholecystitis were more likely to occur in females. A higher percentage of patients in the age 10 - 17 group were female (72.2% vs. 52.7%, P < 0.01) and Hispanic (33.4% vs. 22.7%, P < 0.01) compared to the age 0 - 9 group. Age 0 - 5 and male gender were associated with lower routine home discharge rates and longer lengths of stay. Complications occurred at a higher rate in ages 0 - 5, though the difference was not statistically significant.</p><p><strong>Conclusions: </strong>ERCP is a safe procedure for pediatric patients with low complication rates and rare mortality. We found statistically significant differences in the procedure indications between pediatric age groups, races, and genders. Age ≤ 5 years and male gender were associated with more complicated healthcare courses.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 6","pages":"314-324"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/4d/gr-15-314.PMC9822666.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10554199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Radiation in Gastroenterology. 胃肠病学中的放射。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 DOI: 10.14740/gr1567
Monjur Ahmed, Razin Ahmed

The benefit of radiation is immense in the field of gastroenterology. Radiation is used daily in different gastrointestinal imaging and diagnostic and therapeutic interventional procedures. Radiotherapy is one of the primary modalities of treatment of gastrointestinal malignancies. There are various modalities of radiotherapy. Radiotherapy can injure malignant cells by directly damaging DNA, RNA, proteins, and lipids and indirectly by forming free radicals. External beam radiation, internal beam radiation and radio-isotope therapy are the major ways of delivering radiation to the malignant tissue. Radiation can also cause inflammation, fibrosis, organ dysfunction, and malignancy. Patients with repeated exposure to radiation for diagnostic imaging and therapeutic procedures are at slightly increased risk of malignancy. Gastrointestinal endoscopists performing fluoroscopy-guided procedures are also at increased risk of malignancy and cataract formation. The radiological protection society recommends certain preventive and protective measures to avoid side effects of radiation. Gastrointestinal complications related to radiation therapy for oncologic processes, and exposure risks for patients and health care providers involved in diagnostic or therapeutic imaging will be discussed in this review.

放射治疗在胃肠病学领域的益处是巨大的。辐射每天用于不同的胃肠道成像和诊断和治疗介入程序。放射治疗是治疗胃肠道恶性肿瘤的主要方式之一。放射治疗有多种方式。放射治疗可以通过直接破坏DNA、RNA、蛋白质和脂质以及通过形成自由基间接伤害恶性细胞。外束放疗、内束放疗和放射性同位素治疗是恶性肿瘤组织放射治疗的主要方式。辐射还会引起炎症、纤维化、器官功能障碍和恶性肿瘤。在诊断成像和治疗过程中反复暴露于辐射的患者患恶性肿瘤的风险略有增加。胃肠内窥镜医师在进行透视引导的手术时,患恶性肿瘤和白内障的风险也会增加。放射防护学会建议采取某些预防和防护措施,以避免辐射的副作用。本综述将讨论肿瘤过程中与放射治疗相关的胃肠道并发症,以及参与诊断或治疗成像的患者和卫生保健提供者的暴露风险。
{"title":"Radiation in Gastroenterology.","authors":"Monjur Ahmed,&nbsp;Razin Ahmed","doi":"10.14740/gr1567","DOIUrl":"https://doi.org/10.14740/gr1567","url":null,"abstract":"<p><p>The benefit of radiation is immense in the field of gastroenterology. Radiation is used daily in different gastrointestinal imaging and diagnostic and therapeutic interventional procedures. Radiotherapy is one of the primary modalities of treatment of gastrointestinal malignancies. There are various modalities of radiotherapy. Radiotherapy can injure malignant cells by directly damaging DNA, RNA, proteins, and lipids and indirectly by forming free radicals. External beam radiation, internal beam radiation and radio-isotope therapy are the major ways of delivering radiation to the malignant tissue. Radiation can also cause inflammation, fibrosis, organ dysfunction, and malignancy. Patients with repeated exposure to radiation for diagnostic imaging and therapeutic procedures are at slightly increased risk of malignancy. Gastrointestinal endoscopists performing fluoroscopy-guided procedures are also at increased risk of malignancy and cataract formation. The radiological protection society recommends certain preventive and protective measures to avoid side effects of radiation. Gastrointestinal complications related to radiation therapy for oncologic processes, and exposure risks for patients and health care providers involved in diagnostic or therapeutic imaging will be discussed in this review.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 6","pages":"285-296"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/0d/gr-15-285.PMC9822665.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10558658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Barriers to Hepatitis C Virus Care and How Federally Qualified Health Centers Can Improve Patient Access to Treatment. 丙型肝炎病毒治疗的障碍以及联邦合格医疗中心如何改善患者获得治疗的机会。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 DOI: 10.14740/gr1568
David Lam, Robert J Wong, Adla Tessier, Yenice Zapata, Elsie Saldana, Robert G Gish
<p><strong>Background: </strong>Despite the availability of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, disparities in HCV care and treatment persist for underserved populations due to demographic-based and insurance-based barriers. We aim to examine the effect of barriers on HCV treatment access for a federally qualified health center (FQHC) population.</p><p><strong>Methods: </strong>We retrospectively evaluated medical records of adults diagnosed with chronic HCV at an FQHC clinic from 2016 to 2020 with follow-up through 2021. Univariate and bivariate analyses were used to describe the patient population and significant associations between predictors of linkage to HCV care and treatment access. Adjusted multivariate logistic regression analyses were used to identify predictors of starting HCV treatment.</p><p><strong>Results: </strong>Of 279 total patients with chronic HCV, 162 patients started treatment (58%), 138 patients (50%) completed treatment, and 99 patients (35%) achieved sustained virological response (SVR). Of the total patients, 145 (52%) were seen by their primary care physician (PCP) for their HCV care and treatment, and 134 (48%) were seen by a provider that specializes in management and treatment of HCV (HCV provider). Patients seen by an HCV provider in addition to their PCP were more likely to have had their prior authorization requests for HCV treatment denied by their insurance providers than patients seen only by their PCP for HCV care (30% vs. 14%, P = 0.001). We believe that this discrepancy stems from two issues. One, prior authorizations are reviewed by insurance providers who are not specially trained in HCV management, so the verbiage used perplexes these reviewers, possibly causing them to issue denials. Two, insurance providers often require HCV genotype testing for DAA medication eligibility, and HCV providers order genotype tests for patients only when HCV treatments have failed to cure patients, so this requirement becomes another barrier to DAA medications. Patients who spoke a non-English language, lived in the USA for less than 10 years, and showed inability to pay for treatment had received treatment despite these characteristics being common barriers to HCV treatment. On multivariate regression, factors independently associated with patients starting treatment included prior denial for DAA medication (odds ratio (OR), 8.88; 95% confidence interval (CI), 3.22 - 24.6; P < 0.001) and being seen by an HCV provider (OR, 24.8; 95% CI, 11.7 - 52.5; P < 0.001). However, the most significant barrier to HCV treatment access for the FQHC population was eligibility restrictions from insurance providers.</p><p><strong>Conclusions: </strong>Demographic-based barriers (e.g., age, race, and income) often impede HCV care and treatment, but insurance-based barriers are the greatest challenge currently that affects treatment outcomes in our study population. Removing these restrictions would,
背景:尽管直接作用抗病毒药物(DAAs)可用于治疗丙型肝炎病毒(HCV),但由于人口和保险方面的障碍,在服务不足的人群中,丙型肝炎病毒的护理和治疗仍然存在差异。我们的目的是检查障碍对联邦合格健康中心(FQHC)人群HCV治疗可及性的影响。方法:回顾性评估2016年至2020年FQHC诊所诊断为慢性HCV的成人病历,随访至2021年。单变量和双变量分析用于描述患者群体以及与HCV护理和治疗可及性相关的预测因子之间的显著关联。采用调整后的多变量logistic回归分析来确定开始HCV治疗的预测因素。结果:279例慢性HCV患者中,162例患者开始治疗(58%),138例患者(50%)完成治疗,99例患者(35%)获得持续病毒学应答(SVR)。在所有患者中,145名(52%)患者接受了初级保健医生(PCP)的HCV护理和治疗,134名(48%)患者接受了专门从事HCV管理和治疗的提供者(HCV提供者)的治疗。与仅接受PCP治疗的HCV患者相比,接受PCP治疗的HCV患者更有可能被保险提供者拒绝其事先授权的HCV治疗请求(30%比14%,P = 0.001)。我们认为,这种差异源于两个问题。首先,事先的授权是由没有经过HCV管理专门培训的保险提供商审查的,因此使用的措辞使这些审查员感到困惑,可能导致他们发布拒绝。第二,保险公司通常要求进行HCV基因型检测以确定DAA的用药资格,而只有当HCV治疗无法治愈患者时,HCV供应商才会对患者进行基因型检测,因此这一要求成为DAA药物的另一个障碍。尽管这些特征是HCV治疗的常见障碍,但讲非英语语言、在美国居住不到10年、表现出无力支付治疗费用的患者仍接受了治疗。在多变量回归中,与患者开始治疗独立相关的因素包括先前拒绝使用DAA药物(优势比(OR), 8.88;95%置信区间(CI), 3.22 ~ 24.6;P < 0.001)和被HCV提供者看到(OR, 24.8;95% ci, 11.7 - 52.5;P < 0.001)。然而,FQHC人群获得HCV治疗的最大障碍是保险提供商的资格限制。结论:基于人口统计学的障碍(如年龄、种族和收入)经常阻碍HCV的护理和治疗,但基于保险的障碍是目前影响我们研究人群治疗结果的最大挑战。我们认为,取消这些限制将有助于提高对服务不足人口的治疗水平。
{"title":"Barriers to Hepatitis C Virus Care and How Federally Qualified Health Centers Can Improve Patient Access to Treatment.","authors":"David Lam,&nbsp;Robert J Wong,&nbsp;Adla Tessier,&nbsp;Yenice Zapata,&nbsp;Elsie Saldana,&nbsp;Robert G Gish","doi":"10.14740/gr1568","DOIUrl":"https://doi.org/10.14740/gr1568","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Despite the availability of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, disparities in HCV care and treatment persist for underserved populations due to demographic-based and insurance-based barriers. We aim to examine the effect of barriers on HCV treatment access for a federally qualified health center (FQHC) population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We retrospectively evaluated medical records of adults diagnosed with chronic HCV at an FQHC clinic from 2016 to 2020 with follow-up through 2021. Univariate and bivariate analyses were used to describe the patient population and significant associations between predictors of linkage to HCV care and treatment access. Adjusted multivariate logistic regression analyses were used to identify predictors of starting HCV treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 279 total patients with chronic HCV, 162 patients started treatment (58%), 138 patients (50%) completed treatment, and 99 patients (35%) achieved sustained virological response (SVR). Of the total patients, 145 (52%) were seen by their primary care physician (PCP) for their HCV care and treatment, and 134 (48%) were seen by a provider that specializes in management and treatment of HCV (HCV provider). Patients seen by an HCV provider in addition to their PCP were more likely to have had their prior authorization requests for HCV treatment denied by their insurance providers than patients seen only by their PCP for HCV care (30% vs. 14%, P = 0.001). We believe that this discrepancy stems from two issues. One, prior authorizations are reviewed by insurance providers who are not specially trained in HCV management, so the verbiage used perplexes these reviewers, possibly causing them to issue denials. Two, insurance providers often require HCV genotype testing for DAA medication eligibility, and HCV providers order genotype tests for patients only when HCV treatments have failed to cure patients, so this requirement becomes another barrier to DAA medications. Patients who spoke a non-English language, lived in the USA for less than 10 years, and showed inability to pay for treatment had received treatment despite these characteristics being common barriers to HCV treatment. On multivariate regression, factors independently associated with patients starting treatment included prior denial for DAA medication (odds ratio (OR), 8.88; 95% confidence interval (CI), 3.22 - 24.6; P &lt; 0.001) and being seen by an HCV provider (OR, 24.8; 95% CI, 11.7 - 52.5; P &lt; 0.001). However, the most significant barrier to HCV treatment access for the FQHC population was eligibility restrictions from insurance providers.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Demographic-based barriers (e.g., age, race, and income) often impede HCV care and treatment, but insurance-based barriers are the greatest challenge currently that affects treatment outcomes in our study population. Removing these restrictions would,","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 6","pages":"343-352"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/77/gr-15-343.PMC9822664.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10558663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Unusual Solitary Fibrous Tumor of the Ischiorectal Region. 坐骨直肠区罕见的孤立性纤维性肿瘤。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1539
Mahmoud R A Hussein, Abdullah Saad Alqahtani, Mubarak Mohammed Al-Shraim, Yahia Ibraheem Assiri, Feras O Ahmed, Mohammed Jalwi Korkoman, Ahmed Y Al-Ameer, Asmaa M Ahmed

Solitary fibrous tumors (SFTs) are rare fibroblastic/myofibroblastic proliferations that occur in a wide range of anatomical sites. These tumors have nonspecific clinical presentations often with unpredictable biological behavior. SFTs can be slow growing low-risk tumors or rapidly growing high-risk tumors. They show a wide variety of histological features and typically are characterized by NAB2-STAT6 fusion. SFTs of the ischiorectal fossa are rare, with few studies reported in the literature to date. Here, we report a 90-year-old male who had a road traffic accident in October 2018. A pelvic computed tomography (CT) revealed a mass measuring 3.5 × 2.5 cm in the right ischiorectal fossa. Histopathology of the CT-guided biopsies confirmed the diagnosis of low-grade SFT. No surgical intervention was needed since the patient was asymptomatic. In January 2022, a follow-up CT showed a gradual increase in tumor size (5 × 3.5 × 3 cm), but not infiltrating the surrounding structures. However, the patient complained of constipation, which warranted a surgical excision of the mass. Subsequently, immunohistological examination reconfirmed the diagnosis of low-risk SFT. Here, we discussed the clinicopathological features of the case and the relevant literature about pelvic SFTs. In conclusion, SFTs should be considered in the differential diagnosis of any ischiorectal mass. It is recommended that tissue samples be obtained, and immunohistology should be performed.

孤立性纤维性肿瘤(SFTs)是罕见的纤维母细胞/肌纤维母细胞增生,发生在广泛的解剖部位。这些肿瘤具有非特异性的临床表现,通常具有不可预测的生物学行为。SFTs可以是生长缓慢的低风险肿瘤,也可以是生长迅速的高风险肿瘤。它们表现出多种组织学特征,并以NAB2-STAT6融合为典型特征。坐骨直肠窝的SFTs是罕见的,迄今为止文献报道的研究很少。在这里,我们报告了一名90岁的男性,他在2018年10月发生了一起道路交通事故。骨盆计算机断层扫描(CT)显示在右侧坐骨直肠窝有3.5 × 2.5 cm的肿块。ct引导下的组织病理学证实了低级别SFT的诊断。由于患者无症状,无需手术干预。2022年1月随访CT示肿瘤大小逐渐增大(5 × 3.5 × 3cm),但未浸润周围结构。然而,病人主诉便秘,需要手术切除肿块。随后,免疫组织学检查再次确诊为低危性SFT。在此,我们讨论了该病例的临床病理特征和盆腔SFTs的相关文献。总之,在任何坐骨直肠肿块的鉴别诊断中都应考虑SFTs。建议获得组织样本,并进行免疫组织学检查。
{"title":"An Unusual Solitary Fibrous Tumor of the Ischiorectal Region.","authors":"Mahmoud R A Hussein,&nbsp;Abdullah Saad Alqahtani,&nbsp;Mubarak Mohammed Al-Shraim,&nbsp;Yahia Ibraheem Assiri,&nbsp;Feras O Ahmed,&nbsp;Mohammed Jalwi Korkoman,&nbsp;Ahmed Y Al-Ameer,&nbsp;Asmaa M Ahmed","doi":"10.14740/gr1539","DOIUrl":"https://doi.org/10.14740/gr1539","url":null,"abstract":"<p><p>Solitary fibrous tumors (SFTs) are rare fibroblastic/myofibroblastic proliferations that occur in a wide range of anatomical sites. These tumors have nonspecific clinical presentations often with unpredictable biological behavior. SFTs can be slow growing low-risk tumors or rapidly growing high-risk tumors. They show a wide variety of histological features and typically are characterized by <i>NAB2-STAT6</i> fusion. SFTs of the ischiorectal fossa are rare, with few studies reported in the literature to date. Here, we report a 90-year-old male who had a road traffic accident in October 2018. A pelvic computed tomography (CT) revealed a mass measuring 3.5 × 2.5 cm in the right ischiorectal fossa. Histopathology of the CT-guided biopsies confirmed the diagnosis of low-grade SFT. No surgical intervention was needed since the patient was asymptomatic. In January 2022, a follow-up CT showed a gradual increase in tumor size (5 × 3.5 × 3 cm), but not infiltrating the surrounding structures. However, the patient complained of constipation, which warranted a surgical excision of the mass. Subsequently, immunohistological examination reconfirmed the diagnosis of low-risk SFT. Here, we discussed the clinicopathological features of the case and the relevant literature about pelvic SFTs. In conclusion, SFTs should be considered in the differential diagnosis of any ischiorectal mass. It is recommended that tissue samples be obtained, and immunohistology should be performed.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"268-277"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/c0/gr-15-268.PMC9635781.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Accuracy of Elastography and Liver Disease: A Meta-Analysis. 弹性成像和肝脏疾病的诊断准确性:一项荟萃分析。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1557
Preeti Malik, Shreejith Pillai, Kriti Agarwal, Salwa Abdelwahed, Renu Bhandari, Abhishek Singh, Anusha Chidharla, Kajal Patel, Priyanka Singh, Pritika Manaktala, Rizwan Rabbani, Thoyaja Koritala, Sachin Gupta

Background: Ultrasound-based transient elastography (TE) is a non-invasive alternative to liver biopsy for the staging of hepatic fibrosis due to various chronic liver diseases. This meta-analysis aims to assess the diagnostic accuracy of TE for detecting liver cirrhosis (F4) and severe fibrosis (F3) in patients with chronic liver diseases, in comparison to the gold standard liver biopsy.

Methods: A systematic search was performed using PubMed search engine following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines from inception to May 2021. The meta-analysis studies evaluating the diagnostic accuracy of TE for severe fibrosis and cirrhosis were identified. We conducted a meta-meta-analysis to generate pooled estimates of the sensitivity, specificity, and diagnostic odds ratios (ORs) for F3 and F4 fibrosis stage.

Results: We included five studies with a total of 124 sub-studies and 20,341 patients in our analysis. Three studies have reported the diagnostic accuracy of TE in detecting F3/severe fibrosis stage and found 81.9% pooled sensitivity (95% confidence interval (CI): 79.9-83.7%; P < 0.001) (I2 = 0%), 84.7% pooled specificity (95% CI: 81.3-87.6%) (I2 = 81%; P = 0.02). All five studies reported the diagnostic accuracy of TE in detecting F4/liver cirrhosis stage. We found 84.8% pooled sensitivity (95% CI: 81.4-87.7%) (I2 = 86.4%; P < 0.001), 87.5% pooled specificity (95% CI: 85.4-89.3%) (I2 = 90%; P < 0.001) and pooled diagnostic OR (41.8; 95% CI: 3.9 - 56.5) (I2 = 87%; P < 0.001).

Conclusions: Ultrasound-based TE has excellent diagnostic accuracy for identifying cirrhosis and liver fibrosis stages 3. Future studies should focus on estimating the diagnostic accuracy of other fibrosis stages in chronic liver disease patients. This will eventually decrease the risk associated with invasive liver biopsy.

背景:基于超声的瞬时弹性成像(TE)是一种非侵入性替代肝活检的方法,用于各种慢性肝病引起的肝纤维化分期。本荟萃分析旨在评估TE检测慢性肝病患者肝硬化(F4)和严重纤维化(F3)的诊断准确性,并与金标准肝活检进行比较。方法:使用PubMed搜索引擎,按照系统评价和荟萃分析(PRISMA)指南的首选报告项目进行系统搜索,从成立到2021年5月。meta分析研究评估了TE对严重纤维化和肝硬化的诊断准确性。我们进行了一项荟萃分析,对F3和F4纤维化分期的敏感性、特异性和诊断优势比(ORs)进行汇总估计。结果:我们在分析中纳入了5项研究,共124个亚研究和20341名患者。三项研究报道了TE在检测F3/严重纤维化阶段的诊断准确性,发现合并敏感性为81.9%(95%可信区间(CI): 79.9-83.7%;P < 0.001) (I2 = 0%),合并特异性为84.7% (95% CI: 81.3-87.6%) (I2 = 81%;P = 0.02)。5项研究均报道了TE对F4/肝硬化分期的诊断准确性。我们发现合并敏感性为84.8% (95% CI: 81.4-87.7%) (I2 = 86.4%;P < 0.001), 87.5%的合并特异性(95% CI: 85.4-89.3%) (I2 = 90%;P < 0.001)和合并诊断OR (41.8;95% ci: 3.9 - 56.5) (i2 = 87%;P < 0.001)。结论:基于超声的TE诊断肝硬化和肝纤维化3期具有很好的准确性。未来的研究应侧重于评估慢性肝病患者其他纤维化分期的诊断准确性。这将最终降低与侵入性肝活检相关的风险。
{"title":"Diagnostic Accuracy of Elastography and Liver Disease: A Meta-Analysis.","authors":"Preeti Malik,&nbsp;Shreejith Pillai,&nbsp;Kriti Agarwal,&nbsp;Salwa Abdelwahed,&nbsp;Renu Bhandari,&nbsp;Abhishek Singh,&nbsp;Anusha Chidharla,&nbsp;Kajal Patel,&nbsp;Priyanka Singh,&nbsp;Pritika Manaktala,&nbsp;Rizwan Rabbani,&nbsp;Thoyaja Koritala,&nbsp;Sachin Gupta","doi":"10.14740/gr1557","DOIUrl":"https://doi.org/10.14740/gr1557","url":null,"abstract":"<p><strong>Background: </strong>Ultrasound-based transient elastography (TE) is a non-invasive alternative to liver biopsy for the staging of hepatic fibrosis due to various chronic liver diseases. This meta-analysis aims to assess the diagnostic accuracy of TE for detecting liver cirrhosis (F4) and severe fibrosis (F3) in patients with chronic liver diseases, in comparison to the gold standard liver biopsy.</p><p><strong>Methods: </strong>A systematic search was performed using PubMed search engine following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines from inception to May 2021. The meta-analysis studies evaluating the diagnostic accuracy of TE for severe fibrosis and cirrhosis were identified. We conducted a meta-meta-analysis to generate pooled estimates of the sensitivity, specificity, and diagnostic odds ratios (ORs) for F3 and F4 fibrosis stage.</p><p><strong>Results: </strong>We included five studies with a total of 124 sub-studies and 20,341 patients in our analysis. Three studies have reported the diagnostic accuracy of TE in detecting F3/severe fibrosis stage and found 81.9% pooled sensitivity (95% confidence interval (CI): 79.9-83.7%; P < 0.001) (I<sup>2</sup> = 0%), 84.7% pooled specificity (95% CI: 81.3-87.6%) (I<sup>2</sup> = 81%; P = 0.02). All five studies reported the diagnostic accuracy of TE in detecting F4/liver cirrhosis stage. We found 84.8% pooled sensitivity (95% CI: 81.4-87.7%) (I<sup>2</sup> = 86.4%; P < 0.001), 87.5% pooled specificity (95% CI: 85.4-89.3%) (I<sup>2</sup> = 90%; P < 0.001) and pooled diagnostic OR (41.8; 95% CI: 3.9 - 56.5) (I<sup>2</sup> = 87%; P < 0.001).</p><p><strong>Conclusions: </strong>Ultrasound-based TE has excellent diagnostic accuracy for identifying cirrhosis and liver fibrosis stages 3. Future studies should focus on estimating the diagnostic accuracy of other fibrosis stages in chronic liver disease patients. This will eventually decrease the risk associated with invasive liver biopsy.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"232-239"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/4d/gr-15-232.PMC9635782.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The Supportive Role of Provocative Maneuvers and Impedance Clearance in Detecting Ineffective Esophageal Motility. 刺激动作和阻抗清除在检测无效食管运动中的支持作用。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1552
Virali Shah, Alla Turshudzhyan, Alexandra Mignucci, Micheal Tadros

Background: Ineffective esophageal motility (IEM) is one of the most common esophageal motility disorders. However, the definition of IEM has evolved. Chicago classification version 4.0 (CCv4.0) made IEM parameters more stringent with greater than 70% of ineffective wet swallows (WS) necessary to diagnose conclusive IEM. Of the ineffective swallows, 50-70% are deemed "inconclusive cases". This study sought to determine whether provocative maneuvers, including multiple rapid swallows (MRS) and apple viscous swallows (AVS), and impedance clearance can provide supportive information for inconclusive IEM disorders based on CCv4.0.

Methods: Esophageal motility data on 100 patients were analyzed. All patients completed WS and at least one additional swallow test (MRS and/or AVS). Patients were classified as having conclusive IEM, inconclusive IEM, or normal motility. IEM features detected on MRS/AVS and incomplete bolus clearance were recorded. Percentage of agreement between IEM features and incomplete bolus clearance was calculated for each motility group.

Results: Ten patients had conclusive IEM, nine had inconclusive IEM, and 32 had normal motility. There was 70% agreement between IEM features and incomplete bolus clearance with conclusive IEM, 33% agreement with inconclusive IEM, and 9% agreement with normal motility. There was significantly more agreement in the conclusive and inconclusive IEM groups than in the normal motility group (P = 0.0003).

Conclusions: Combinational follow-up testing with provocative maneuvers and impedance clearance may assist with risk stratification of IEM patients and assist in further management of inconclusive IEM. MRS and AVS can detect unique IEM features that may help with preoperative management of inconclusive IEM.

背景:食道运动障碍是最常见的食道运动障碍之一。然而,IEM的定义已经发生了变化。芝加哥分类4.0 (CCv4.0)使IEM参数更加严格,诊断结论性IEM所需的无效湿咽(WS)大于70%。在无效的燕子中,50-70%被认为是“不确定的病例”。本研究旨在确定挑衅动作,包括多次快速燕子(MRS)和苹果粘性燕子(AVS),以及阻抗清除是否可以为基于CCv4.0的不确定IEM障碍提供支持性信息。方法:对100例患者的食管运动资料进行分析。所有患者均完成WS和至少一项额外的吞咽试验(MRS和/或AVS)。患者分为结论性IEM、非结论性IEM和运动正常。记录MRS/AVS检测到的IEM特征和不完全的丸清除。计算每个运动组IEM特征与不完全丸清除之间的一致性百分比。结果:结论性IEM 10例,不结论性IEM 9例,运动正常32例。IEM特征与不完全清除与结论性IEM的一致性为70%,与不结论性IEM的一致性为33%,与正常运动的一致性为9%。结论性和非结论性IEM组的一致性明显高于正常运动组(P = 0.0003)。结论:联合随访试验与刺激动作和阻抗清除可能有助于IEM患者的风险分层,并有助于进一步治疗不确定的IEM。MRS和AVS可以检测出独特的IEM特征,可能有助于术前管理不确定的IEM。
{"title":"The Supportive Role of Provocative Maneuvers and Impedance Clearance in Detecting Ineffective Esophageal Motility.","authors":"Virali Shah,&nbsp;Alla Turshudzhyan,&nbsp;Alexandra Mignucci,&nbsp;Micheal Tadros","doi":"10.14740/gr1552","DOIUrl":"https://doi.org/10.14740/gr1552","url":null,"abstract":"<p><strong>Background: </strong>Ineffective esophageal motility (IEM) is one of the most common esophageal motility disorders. However, the definition of IEM has evolved. Chicago classification version 4.0 (CCv4.0) made IEM parameters more stringent with greater than 70% of ineffective wet swallows (WS) necessary to diagnose conclusive IEM. Of the ineffective swallows, 50-70% are deemed \"inconclusive cases\". This study sought to determine whether provocative maneuvers, including multiple rapid swallows (MRS) and apple viscous swallows (AVS), and impedance clearance can provide supportive information for inconclusive IEM disorders based on CCv4.0.</p><p><strong>Methods: </strong>Esophageal motility data on 100 patients were analyzed. All patients completed WS and at least one additional swallow test (MRS and/or AVS). Patients were classified as having conclusive IEM, inconclusive IEM, or normal motility. IEM features detected on MRS/AVS and incomplete bolus clearance were recorded. Percentage of agreement between IEM features and incomplete bolus clearance was calculated for each motility group.</p><p><strong>Results: </strong>Ten patients had conclusive IEM, nine had inconclusive IEM, and 32 had normal motility. There was 70% agreement between IEM features and incomplete bolus clearance with conclusive IEM, 33% agreement with inconclusive IEM, and 9% agreement with normal motility. There was significantly more agreement in the conclusive and inconclusive IEM groups than in the normal motility group (P = 0.0003).</p><p><strong>Conclusions: </strong>Combinational follow-up testing with provocative maneuvers and impedance clearance may assist with risk stratification of IEM patients and assist in further management of inconclusive IEM. MRS and AVS can detect unique IEM features that may help with preoperative management of inconclusive IEM.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"225-231"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/da/gr-15-225.PMC9635783.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Development of a Predictive Model for Common Bile Duct Stones in Patients With Clinical Suspicion of Choledocholithiasis: A Cohort Study. 临床怀疑胆总管结石患者胆总管结石预测模型的建立:一项队列研究。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1560
Suppadech Tunruttanakul, Kotchakorn Verasmith, Jayanton Patumanond, Chatchai Mingmalairak

Background: Current choledocholithiasis guidelines heavily focus on patients with low or no risk, they may be inappropriate for populations with high rates of choledocholithiasis. We aimed to develop a predictive scoring model for choledocholithiasis in patients with relevant clinical manifestations.

Methods: A multivariable predictive model development study based on a retrospective cohort of patients with clinical suspicion of choledocholithiasis was used in this study. The setting was a 700-bed public tertiary hospital. Participants were patients who had completed three reference tests (endoscopic retrograde cholangiography, magnetic resonance cholangiopancreatography, and intraoperative cholangiography) from January 2019 to June 2021. The model was developed using logistic regression analysis. Predictor selection was conducted using a backward stepwise approach. Three risk groups were considered. Model performance was evaluated by area under the receiver operating characteristic curve, calibration, classification measures, and decision curve analyses.

Results: Six hundred twenty-one patients were included; the choledocholithiasis prevalence was 59.9%. The predictors were age > 55 years, pancreatitis, cholangitis, cirrhosis, alkaline phosphatase level of 125 - 250 or > 250 U/L, total bilirubin level > 4 mg/dL, common bile duct size > 6 mm, and common bile duct stone detection. Pancreatitis and cirrhosis each had a negative score. The sum of scores was -4.5 to 28.5. Patients were categorized into three risk groups: low-intermediate (score ≤ 5), intermediate (score 5.5 - 14.5), and high (score ≥ 15). Positive likelihood ratios were 0.16 and 3.47 in the low-intermediate and high-risk groups, respectively. The model had an area under the receiver operating characteristic curve of 0.80 (95% confidence interval: 0.76, 0.83) and was well-calibrated; it exhibited better statistical suitability to the high-prevalence population, compared to current guidelines.

Conclusions: Our scoring model had good predictive ability for choledocholithiasis in patients with relevant clinical manifestations. Consideration of other factors is necessary for clinical application, particularly regarding the availability of expert physicians and specialized equipment.

背景:目前的胆总管结石指南主要侧重于低风险或无风险的患者,它们可能不适合胆总管结石高发人群。我们的目的是为有相关临床表现的胆总管结石患者建立一个预测评分模型。方法:基于临床疑似胆总管结石患者的回顾性队列,采用多变量预测模型开发研究。事发地点是一家拥有700张床位的公立三级医院。参与者是在2019年1月至2021年6月期间完成了三次参考检查(内窥镜逆行胆管造影、磁共振胆管造影术和术中胆管造影)的患者。该模型采用logistic回归分析。预测因子选择采用后向逐步方法。考虑了三个风险群体。通过受试者工作特征曲线下的面积、校准、分类措施和决策曲线分析来评估模型的性能。结果:共纳入621例患者;胆总管结石患病率为59.9%。预测因素为年龄> 55岁、胰腺炎、胆管炎、肝硬化、碱性磷酸酶水平125 - 250或> 250 U/L、总胆红素水平> 4 mg/dL、总胆管尺寸> 6 mm、总胆管结石检测。胰腺炎和肝硬化的评分均为阴性。总分在-4.5到28.5之间。患者分为中低危组(评分≤5)、中危组(评分5.5 ~ 14.5)和高危组(评分≥15)。低、中、高危组的阳性似然比分别为0.16和3.47。该模型的受试者工作特征曲线下面积为0.80(95%置信区间:0.76,0.83),校准良好;与现行指南相比,它对高患病率人群表现出更好的统计适用性。结论:我们的评分模型对有相关临床表现的胆总管结石患者有较好的预测能力。临床应用需要考虑其他因素,特别是关于专家医生和专业设备的可用性。
{"title":"Development of a Predictive Model for Common Bile Duct Stones in Patients With Clinical Suspicion of Choledocholithiasis: A Cohort Study.","authors":"Suppadech Tunruttanakul,&nbsp;Kotchakorn Verasmith,&nbsp;Jayanton Patumanond,&nbsp;Chatchai Mingmalairak","doi":"10.14740/gr1560","DOIUrl":"https://doi.org/10.14740/gr1560","url":null,"abstract":"<p><strong>Background: </strong>Current choledocholithiasis guidelines heavily focus on patients with low or no risk, they may be inappropriate for populations with high rates of choledocholithiasis. We aimed to develop a predictive scoring model for choledocholithiasis in patients with relevant clinical manifestations.</p><p><strong>Methods: </strong>A multivariable predictive model development study based on a retrospective cohort of patients with clinical suspicion of choledocholithiasis was used in this study. The setting was a 700-bed public tertiary hospital. Participants were patients who had completed three reference tests (endoscopic retrograde cholangiography, magnetic resonance cholangiopancreatography, and intraoperative cholangiography) from January 2019 to June 2021. The model was developed using logistic regression analysis. Predictor selection was conducted using a backward stepwise approach. Three risk groups were considered. Model performance was evaluated by area under the receiver operating characteristic curve, calibration, classification measures, and decision curve analyses.</p><p><strong>Results: </strong>Six hundred twenty-one patients were included; the choledocholithiasis prevalence was 59.9%. The predictors were age > 55 years, pancreatitis, cholangitis, cirrhosis, alkaline phosphatase level of 125 - 250 or > 250 U/L, total bilirubin level > 4 mg/dL, common bile duct size > 6 mm, and common bile duct stone detection. Pancreatitis and cirrhosis each had a negative score. The sum of scores was -4.5 to 28.5. Patients were categorized into three risk groups: low-intermediate (score ≤ 5), intermediate (score 5.5 - 14.5), and high (score ≥ 15). Positive likelihood ratios were 0.16 and 3.47 in the low-intermediate and high-risk groups, respectively. The model had an area under the receiver operating characteristic curve of 0.80 (95% confidence interval: 0.76, 0.83) and was well-calibrated; it exhibited better statistical suitability to the high-prevalence population, compared to current guidelines.</p><p><strong>Conclusions: </strong>Our scoring model had good predictive ability for choledocholithiasis in patients with relevant clinical manifestations. Consideration of other factors is necessary for clinical application, particularly regarding the availability of expert physicians and specialized equipment.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"240-252"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/78/gr-15-240.PMC9635785.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Rates, Reasons, and Independent Predictors of Readmissions in Portal Venous Thrombosis Hospitalizations in the USA. 美国门静脉血栓再入院的比率、原因和独立预测因素。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1561
Robert Kwei-Nsoro, Pius Ojemolon, Hisham Laswi, Ebehiwele Ebhohon, Abdultawab Shaka, Wasey Ali Mir, Abdul Hassan Siddiqui, Jobin Philipose, Hafeez Shaka

Background: Portal vein thrombosis (PVT), generally considered rare, is becoming increasingly recognized with advanced imaging. Limited data exist regarding readmissions in PVT and its burden on the overall healthcare cost. This study aimed to outline the burden of PVT readmissions and identify the modifiable predictors of readmissions.

Methods: The National Readmission Database (NRD) was used to identify PVT admissions from 2016 to 2019. Using the patient demographic and hospital-specific variables within the NRD, we grouped patient encounters into two cohorts, 30- and 90-day readmission cohorts. We assessed comorbidities using the validated Elixhauser comorbidity index. We obtained inpatient mortality rates, mean length of hospital stay (LOS), total hospital cost (THC), and causes of readmissions in both 30- and 90-day readmission cohorts. Using a multivariate Cox regression analysis, we identified the independent predictors of 30-day readmissions.

Results: We identified 17,971 unique index hospitalizations, of which 2,971 (16.5%) were readmitted within 30 days. The top five causes of readmissions in both 30-day and 90-day readmission cohorts were PVT, sepsis, hepatocellular cancer, liver failure, and alcoholic liver cirrhosis. The following independent predictors of 30-day readmission were identified: discharge against medical advice (AMA) (adjusted hazard ratio (aHR) 1.86; P = 0.002); renal failure (aHR 1.44, P = 0.014), metastatic cancer (aHR 1.31, P = 0.016), fluid and electrolyte disorders (aHR 1.20, P = 0.004), diabetes mellitus (aHR 1.31, P = 0.001) and alcohol abuse (aHR 1.31, P ≤ 0.001).

Conclusion: The readmission rate identified in this study was higher than the national average and targeted interventions addressing these factors may help reduce the overall health care costs.

背景:门静脉血栓形成(PVT)通常被认为是罕见的,随着先进的影像学越来越被认识到。关于PVT再入院及其对总体医疗成本负担的数据有限。本研究旨在概述PVT再入院的负担,并确定再入院的可修改预测因素。方法:使用国家再入院数据库(NRD)对2016年至2019年的PVT入院情况进行识别。使用NRD中的患者人口统计学和医院特定变量,我们将患者分组为两个队列,30天和90天再入院队列。我们使用Elixhauser合并症指数评估合并症。在30天和90天的再入院队列中,我们获得了住院死亡率、平均住院时间(LOS)、总住院费用(THC)和再入院原因。使用多变量Cox回归分析,我们确定了30天再入院的独立预测因素。结果:我们确定了17971例独特指数住院,其中2971例(16.5%)在30天内再次入院。在30天和90天的再入院队列中,再入院的前五大原因是PVT、败血症、肝细胞癌、肝功能衰竭和酒精性肝硬化。确定了以下30天再入院的独立预测因素:不遵医嘱出院(调整风险比(aHR) 1.86;P = 0.002);肾衰竭(aHR 1.44, P = 0.014)、转移性癌症(aHR 1.31, P = 0.016)、体液和电解质紊乱(aHR 1.20, P = 0.004)、糖尿病(aHR 1.31, P = 0.001)和酗酒(aHR 1.31, P≤0.001)。结论:本研究确定的再入院率高于全国平均水平,针对这些因素的有针对性的干预措施可能有助于降低总体卫生保健成本。
{"title":"Rates, Reasons, and Independent Predictors of Readmissions in Portal Venous Thrombosis Hospitalizations in the USA.","authors":"Robert Kwei-Nsoro,&nbsp;Pius Ojemolon,&nbsp;Hisham Laswi,&nbsp;Ebehiwele Ebhohon,&nbsp;Abdultawab Shaka,&nbsp;Wasey Ali Mir,&nbsp;Abdul Hassan Siddiqui,&nbsp;Jobin Philipose,&nbsp;Hafeez Shaka","doi":"10.14740/gr1561","DOIUrl":"https://doi.org/10.14740/gr1561","url":null,"abstract":"<p><strong>Background: </strong>Portal vein thrombosis (PVT), generally considered rare, is becoming increasingly recognized with advanced imaging. Limited data exist regarding readmissions in PVT and its burden on the overall healthcare cost. This study aimed to outline the burden of PVT readmissions and identify the modifiable predictors of readmissions.</p><p><strong>Methods: </strong>The National Readmission Database (NRD) was used to identify PVT admissions from 2016 to 2019. Using the patient demographic and hospital-specific variables within the NRD, we grouped patient encounters into two cohorts, 30- and 90-day readmission cohorts. We assessed comorbidities using the validated Elixhauser comorbidity index. We obtained inpatient mortality rates, mean length of hospital stay (LOS), total hospital cost (THC), and causes of readmissions in both 30- and 90-day readmission cohorts. Using a multivariate Cox regression analysis, we identified the independent predictors of 30-day readmissions.</p><p><strong>Results: </strong>We identified 17,971 unique index hospitalizations, of which 2,971 (16.5%) were readmitted within 30 days. The top five causes of readmissions in both 30-day and 90-day readmission cohorts were PVT, sepsis, hepatocellular cancer, liver failure, and alcoholic liver cirrhosis. The following independent predictors of 30-day readmission were identified: discharge against medical advice (AMA) (adjusted hazard ratio (aHR) 1.86; P = 0.002); renal failure (aHR 1.44, P = 0.014), metastatic cancer (aHR 1.31, P = 0.016), fluid and electrolyte disorders (aHR 1.20, P = 0.004), diabetes mellitus (aHR 1.31, P = 0.001) and alcohol abuse (aHR 1.31, P ≤ 0.001).</p><p><strong>Conclusion: </strong>The readmission rate identified in this study was higher than the national average and targeted interventions addressing these factors may help reduce the overall health care costs.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"253-262"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/51/gr-15-253.PMC9635786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Adult Intussusception in Chronic Marijuana Users. 慢性大麻使用者的成人肠套叠。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1554
Jiten P Kothadia, Anwesh Dash, Rajanshu Verma, Kyle Kreitman, Peter D Snell, Mohammad K Ismail

Intussusception is common in children, but it is rare in adults. The most common causes of adult intussusception (AI) are due to a pathological lead point with a common etiology being malignancy. Intra-luminal irritants should be considered the possible etiology of intussusception in patients without a pathological lead point. Marijuana use has increased dramatically in the United States over the last decade. With increasing public acceptance and legalization of marijuana, various adverse side effects have become more prominent. Marijuana has been shown to disrupt gastrointestinal tract motility by inhibiting cholinergic mechanisms. Here we describe four cases of AI who are chronic marijuana users. This well-referenced review gives attention to the harmful effects of marijuana, given the increasing use of marijuana and its derivatives in the United States.

肠套叠在儿童中很常见,但在成人中很少见。成人肠套叠(AI)最常见的原因是由于一个病理先导点,常见的病因是恶性肿瘤。在没有病理线索的患者中,应考虑肠套叠可能的病因。在过去的十年里,大麻的使用在美国急剧增加。随着公众对大麻的接受度和合法化程度的提高,大麻的各种不良副作用也越来越突出。大麻已被证明通过抑制胆碱能机制扰乱胃肠道运动。在这里,我们描述了四个长期吸食大麻的人工智能案例。鉴于大麻及其衍生物在美国的使用日益增加,这篇引用广泛的评论关注了大麻的有害影响。
{"title":"Adult Intussusception in Chronic Marijuana Users.","authors":"Jiten P Kothadia,&nbsp;Anwesh Dash,&nbsp;Rajanshu Verma,&nbsp;Kyle Kreitman,&nbsp;Peter D Snell,&nbsp;Mohammad K Ismail","doi":"10.14740/gr1554","DOIUrl":"https://doi.org/10.14740/gr1554","url":null,"abstract":"<p><p>Intussusception is common in children, but it is rare in adults. The most common causes of adult intussusception (AI) are due to a pathological lead point with a common etiology being malignancy. Intra-luminal irritants should be considered the possible etiology of intussusception in patients without a pathological lead point. Marijuana use has increased dramatically in the United States over the last decade. With increasing public acceptance and legalization of marijuana, various adverse side effects have become more prominent. Marijuana has been shown to disrupt gastrointestinal tract motility by inhibiting cholinergic mechanisms. Here we describe four cases of AI who are chronic marijuana users. This well-referenced review gives attention to the harmful effects of marijuana, given the increasing use of marijuana and its derivatives in the United States.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"278-283"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/1f/gr-15-278.PMC9635787.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of Percutaneous Endoscopic Gastrostomy Placement in Patients With SARS-CoV-2 Infection. 经皮内镜胃造口术在SARS-CoV-2感染患者中的安全性
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1533
Ayushi Shah, Zunirah Ahmed, Fadl Zeineddine, Eamonn M M Quigley
Background Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context. Methods A retrospective chart review identified patients who underwent PEG placement between January 2020 and January 2021 at a single institution. Success was defined as PEG placement and use to provide enteral nutrition with no complications requiring removal within 4 weeks. Results Thirty-six patients with and 104 age- and sex-matched patients without COVID-19 infection were included. More COVID-19 patients were obese, on anticoagulants, had low serum albumin levels and had a tracheostomy in place. Of those patients, 8.3% with COVID-19 developed PEG-related complications compared to 16.3% without (P = 0.28). PEG success rates in patients with and without COVID-19 were similar at 97.2% and 92.3%, respectively (P = 0.44). Conclusion PEG tube placement is comparatively safe in COVID-19 patients who need long-term enteral access.
背景:2019冠状病毒病(COVID-19)可导致依赖呼吸机的慢性呼吸衰竭,需要管饲。与长期鼻胃管置入相比,经皮内镜胃造口术(PEG)置入提供了更可持续的长期肠内通路,副作用更少。出血是公认的PEG置入并发症,许多COVID-19患者正在使用抗血小板/抗凝剂,但在这种情况下,关于PEG管置入安全性的数据很少。方法:回顾性分析了2020年1月至2021年1月在同一家机构接受PEG植入的患者。成功的定义是PEG放置和使用提供肠内营养,没有并发症需要在4周内移除。结果:纳入36例感染患者和104例年龄和性别匹配的未感染COVID-19患者。更多的COVID-19患者肥胖,服用抗凝血剂,血清白蛋白水平低,并进行了气管切开术。在这些患者中,8.3%的COVID-19患者出现了peg相关并发症,而没有出现peg相关并发症的患者为16.3% (P = 0.28)。合并和未合并COVID-19患者的PEG成功率相似,分别为97.2%和92.3% (P = 0.44)。结论:对于需要长期肠内通路的COVID-19患者,置PEG管是相对安全的。
{"title":"Safety of Percutaneous Endoscopic Gastrostomy Placement in Patients With SARS-CoV-2 Infection.","authors":"Ayushi Shah,&nbsp;Zunirah Ahmed,&nbsp;Fadl Zeineddine,&nbsp;Eamonn M M Quigley","doi":"10.14740/gr1533","DOIUrl":"https://doi.org/10.14740/gr1533","url":null,"abstract":"Background Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context. Methods A retrospective chart review identified patients who underwent PEG placement between January 2020 and January 2021 at a single institution. Success was defined as PEG placement and use to provide enteral nutrition with no complications requiring removal within 4 weeks. Results Thirty-six patients with and 104 age- and sex-matched patients without COVID-19 infection were included. More COVID-19 patients were obese, on anticoagulants, had low serum albumin levels and had a tracheostomy in place. Of those patients, 8.3% with COVID-19 developed PEG-related complications compared to 16.3% without (P = 0.28). PEG success rates in patients with and without COVID-19 were similar at 97.2% and 92.3%, respectively (P = 0.44). Conclusion PEG tube placement is comparatively safe in COVID-19 patients who need long-term enteral access.","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"263-267"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/2b/gr-15-263.PMC9635784.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gastroenterology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1